Opening book details…
About this Medicine article
LBA20 Vandetanib plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER positive breast cancer (FURVA): A randomised, double-blind, placebo-controlled, phase II trial by R. Jones; A. Casbard; M. Carucci; J. Smith; K. Ingarfield; J.M.W. Gee; Z. Hudson; F. Alchami; L. Hayward; T. Hickish; D. Hwang; K. McAdam; S. Spensley; S. Waters; D. Wheatley; M. Beresford is a Medicine article available to read on EtoBox.
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- R. Jones; A. Casbard; M. Carucci; J. Smith; K. Ingarfield; J.M.W. Gee; Z. Hudson; F. Alchami; L. Hayward; T. Hickish; D. Hwang; K. McAdam; S. Spensley; S. Waters; D. Wheatley; M. Beresford
- Publisher
- Elsevier BV
- Published
- 2020
- Language
- EN
- Field
- Medicine (Health Sciences)